20 (AIDX) Interest Expenses (2025 - 2026)
20 (AIDX) reported Interest Expenses of $267008.0 for Q1 2026, up 35982.16% on a YoY basis from N/an in Q1 2025, and up 35982.16% quarter-over-quarter from $740.0 in Q1 2025.
20 (AIDX) Interest Expenses (2025 - 2026) Analysis & Trends
20 has reported Interest Expenses for 2 years, with the latest figure at $267008.0 in Q1 2026.
- For the quarter ending Q1 2026, Interest Expenses rose 35982.16% year-over-year to $267008.0; the trailing twelve-month figure through Mar 2026 stood at $267748.0 (changed N/A YoY), and the FY2025 full-year result was $156207.0, up 1135.23% from the prior year.
- Interest Expenses for Q1 2026 stood at $267008.0, up from $740.0 in the prior quarter.
- The five-year high for Interest Expenses was $267008.0 in Q1 2026, with the low at $740.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 154.42 Bn | 147.76 Bn | 6.27 Bn | 174.00 Mn |
| 2 | Stryker | 118.12 Bn | 115.25 Bn | 3.81 Bn | 148.00 Mn |
| 3 | Medtronic | 101.72 Bn | 93.55 Bn | 5.76 Bn | 181.00 Mn |
| 4 | Boston Scientific | 67.19 Bn | 65.98 Bn | 3.61 Bn | 90.00 Mn |
| 5 | Edwards Lifesciences | 50.69 Bn | 47.02 Bn | 1.29 Bn | - |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | -97.17 Mn |
| 7 | Dexcom | 28.09 Bn | 26.97 Bn | 750.30 Mn | - |
| 8 | GE HealthCare Technologies | 28.08 Bn | 26.02 Bn | 1.98 Bn | 96.00 Mn |
| 9 | Steris | 19.80 Bn | 19.37 Bn | 697.10 Mn | 15.10 Mn |
| 10 | 20 | - | - | 62,884.00 | 267,008.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 267,008.00 |
| Mar 31, 2026 | 267,008.00 |
| Mar 31, 2025 | 740.00 |
| Mar 31, 2025 | 740.00 |